At a Glance
- What it is: a small molecule, not a peptide, built to block one enzyme, NNMT (nicotinamide N-methyltransferase).
- Research areas: NNMT activity and the SAM and NAD+ pathway in cells, plus diet-model studies and aged-mouse studies.
- Evidence level: animal and cell studies only. No human trial on PubMed or ClinicalTrials.gov (searched 19 November 2026).
- Who published it: the seven papers this page summarizes share one author, and four of them declare ties to a company he founded.
5-Amino-1MQ 50mg. For research use only.
On this page: Quick facts · What the research found · How it works · Limits · Common questions
5-Amino-1MQ (5-amino-1-methylquinolinium) is a lab-made small molecule designed to block NNMT, an enzyme found in fat tissue and the liver among other places. In obese and diabetic mice, NNMT levels were higher in fat tissue and the liver, which is why researchers began testing NNMT blockers (Kraus et al., 2014).
The studies summarized below were done in mice and rats, plus cells. None were in people.
Quick facts
- Names: 5-Amino-1MQ, 5-amino-1-methylquinolinium, 5A1MQ, 5A-1MQ, 5-AMQ (PubChem, and the papers below).
- What it is: a small molecule (a quinolinium compound), not a peptide. The active part is a charged ion, C10H11N2+, 159.21 g/mol (PubChem CID 950107). It is usually listed as the iodide salt, C10H11IN2, 286.11 g/mol, CAS 42464-96-0 (PubChem CID 66522933). That CAS number belongs to the iodide salt only.
- Target: in enzyme tests it blocked NNMT at about 1 µM, and compounds from its series did not block related SAM-using enzymes or the enzymes of the NAD+ recycling pathway (Neelakantan et al., 2018).
- In rats: a 2021 study built and validated a lab method to measure 5-Amino-1MQ in rat plasma and urine, then used it in a pharmacokinetic study (Awosemo et al., 2021).
- Human trials: none. We found no human study on PubMed and no trial on ClinicalTrials.gov (searched 19 November 2026). With no human trials, it has no drug approval from the FDA.
What the research found, and what it did not
The six studies below were in mice: obese mice in four of them, aged mice in two. All six list the same author, Stanley Watowich. The results are listed as the papers reported them, with their limits.
The first mouse study (Biochemical Pharmacology, 2018). In an 11-day study of diet-induced obese mice on a high-fat diet, treated mice lost about 5.1% of body weight while untreated mice gained about 1.4%. The epididymal white fat pad weighed about 35% less in treated mice. Food intake did not differ between groups, and the authors reported no observable adverse effects. PMID 29155147
Combined with a reduced-calorie diet (Scientific Reports, 2021). Obese mice were switched to a low-fat diet, with or without 5-Amino-1MQ. By the end of the study, the combined group had lost 6.3 grams of body weight against 2.9 grams for diet alone, and about 29% of fat mass against about 3%. The combined group also had lower liver fat. This study did not test the compound in mice kept on the high-fat diet. PMID 33707534
Obese mice kept on a high-fat diet (Diabetes, Obesity and Metabolism, 2024). In a 28-day study, obese mice stayed on a high-fat diet and received one of two doses or none. At the higher dose, mice gained 0.9 grams against 5.4 grams for untreated mice, and 1.3 grams of fat mass against 4.7 grams. The lower dose made little difference to weight gain. In the higher-dose group, the authors also reported lower liver weight and liver fat and better glucose tolerance. Lean mass and food intake did not differ between groups. PMID 39161060
Aged muscle after injury (Biochemical Pharmacology, 2019). In 24-month-old mice with an injured leg muscle, treated for one or three weeks after the injury, muscle stem cells divided and fused more, repairing fibers were nearly twice as large in cross-section, and peak force of the injured muscle was about 70% higher than in untreated mice. PMID 30753815
Aged muscle and exercise (Scientific Reports, 2024). In an 8-week study of female mice aged 22 months, treated sedentary mice had about 40% more grip strength than untreated sedentary mice. Exercise alone gave about 20%, and treatment plus exercise about 60%, both measured against untreated sedentary mice. In sedentary mice, treatment alone did not significantly change muscle mass or fiber size. PMID 38969654
Gut bacteria with a reduced-calorie diet (Scientific Reports, 2022). In obese mice switched to a low-fat diet, the group also given 5-Amino-1MQ had a distinct gut bacteria pattern, with less Erysipelatoclostridium and more Lactobacillus than the diet-only group. PMID 35013352
How it works as an NNMT inhibitor
NNMT takes a methyl group (one carbon and three hydrogens) from a molecule called SAM and attaches it to nicotinamide, a form of vitamin B3 that cells use to make NAD+. Cells also need SAM as a methyl donor for other work, such as tagging histones, the proteins DNA is wrapped around. In mice, knocking NNMT down in fat tissue and the liver raised SAM and NAD+ in fat tissue and raised how much energy the cells used, and those mice gained less weight on a high-fat diet (Kraus et al., 2014). That study used a gene knockdown, not 5-Amino-1MQ.
5-Amino-1MQ was designed to cross cell membranes and block NNMT directly. In lab-grown fat cells, NNMT inhibitors from the same series lowered the NNMT product 1-MNA, raised cell levels of NAD+ and SAM, and lowered fat production (Neelakantan et al., 2018). More on the NAD+ side of this pathway is in the NAD+ research summary.
What the research does not establish
- There is no published human trial of 5-Amino-1MQ. The studies on this page are in mice, rats and cells.
- Mouse diet studies are a standard research tool, and they do not show what happens in people, at what amount, or over what timeframe.
- The seven 5-Amino-1MQ papers summarized on this page all list one shared author, Stanley Watowich (University of Texas Medical Branch). Four of them (PMIDs 33707534, 35013352, 38969654, 39161060) state that he founded Ridgeline Therapeutics and that co-authors work or worked there.
- We found three papers from other groups that used 5-Amino-1MQ in cancer cell or tumor mouse studies (PMID 33645410, PMID 39067875, PMID 41301471). We found none from another group that repeated the diet or aged-muscle results above (PubMed, searched 19 November 2026).
- The longest 5-Amino-1MQ study on this page ran 8 weeks. None measured longer periods.
- These studies were built to measure effects, not safety. There is no human safety data.
Etched Research lists 5-Amino-1MQ 50mg for laboratory research on pre-order. The salt form in that vial has not been confirmed, and no independent lab report is on file for it yet.
Common questions
Is 5-Amino-1MQ a peptide?
No, 5-Amino-1MQ is a small molecule, 5-amino-1-methylquinolinium, built on a quinoline ring with 10 carbon atoms (PubChem). Peptides are chains of amino acids, and it has none. It is often sold alongside peptides, which is where the label comes from.
What is an NNMT inhibitor?
An NNMT inhibitor is a compound that blocks NNMT, the enzyme that moves a methyl group from SAM onto nicotinamide. In mice, lowering NNMT in fat tissue and the liver raised SAM and NAD+ in fat tissue (Kraus et al., 2014). 5-Amino-1MQ comes from a series of small-molecule NNMT inhibitors designed to cross cell membranes, and in enzyme tests compounds from that series did not block related SAM-using enzymes (Neelakantan et al., 2018). It has not been tested in people.
Is 5-Amino-1MQ FDA approved?
No, we found no FDA approval for 5-Amino-1MQ, and no human trial of it registered on ClinicalTrials.gov or published on PubMed (searched 19 November 2026). The published work on it is in cells, mice and rats (Neelakantan et al., 2018, Awosemo et al., 2021).
What did the mouse studies measure?
The mouse diet studies measured body weight, fat mass, liver fat and food intake in obese mice, and no study has tested 5-Amino-1MQ in people. In an 11-day study, obese mice on a high-fat diet lost about 5% of body weight while untreated mice gained about 1.4% (Neelakantan et al., 2018). In a 28-day study, obese mice given the higher of two doses gained less weight than untreated mice, and the lower dose made little difference (Babula et al., 2024). In a study that also switched obese mice to a low-fat diet, treated mice lost about 29% of fat mass against about 3% for diet alone (Sampson et al., 2021).
What side effects have the 5-Amino-1MQ studies recorded?
The 5-Amino-1MQ side effect findings come from mouse studies only, and there is no human safety data. The 2018 study reported no observable adverse effects and no change in food intake over 11 days (Neelakantan et al., 2018). In the 28-day study, the liver enzymes ALT and AST were raised in untreated obese mice and at normal levels in treated obese mice (Babula et al., 2024). These were short animal studies built to measure effects, not safety.
Who has published on 5-Amino-1MQ?
The seven 5-Amino-1MQ studies summarized on this page share one author, Stanley Watowich, and four of them declare ties to Ridgeline Therapeutics, a company he founded. We found three papers from other groups, all cancer cell or tumor mouse work, and none that repeated the diet or aged-muscle results on this page (PubMed, searched 19 November 2026).
Last reviewed 2026-11-19.
New reports, new research.
We send a note when a new lab report is posted or a compound comes back in stock, plus a short list of new research pages in any month we publish some. Never more than one email a week, and nothing else.
For laboratory research use only. Not for human or animal consumption. This page summarizes published studies and is not medical advice.
